Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this double blind clinical trial study is to investigate whether alphacalcidol treatment in obese subjects can affect the resting metabolic rate. Moreover, the investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α) protein which may lead to change in metabic rate following treatment with either alphacalcidol or placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects

NCT01752244

Obesity

UNKNOWN NA

Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women

NCT01344161

Overweight Obesity

COMPLETED PHASE3

The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity

NCT01405352

Obesity

UNKNOWN PHASE4

Vitamin D Effects in Overweight Patients

NCT00493012

Overweight Obesity

COMPLETED NA

Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents

NCT00994396

Obesity Glucose Intolerance Inflammation

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D analogue

1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.

Group Type EXPERIMENTAL

Vitamin D analogue

Intervention Type DIETARY_SUPPLEMENT

1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks

Placebo

Corn oil pearl Capsules 1 gram

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Vitamin D analogue

1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

corn oil capsule 1-α hydroxyvitamin D3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age 22-52 years Body mass index equal or more than 30

Exclusion Criteria

Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History of any condition affecting inflammatory markers Thyroid diseases Malignancies Current smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections Hepatic or renal diseases Use of PPARγ agonist drug

Minimum Eligible Age

22 Years

Maximum Eligible Age

52 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes